Real-World Patient Outcomes on the Efficacy of Lanreotide Treatment for Neuroendocrine Tumors: The Influence of Body Mass Index, Body Surface Area, and Renal Function
Neuroendocrinology · 2025
DOI: 10.1159/000548257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, 2025. Verfasst von Ilse de Weert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Location Vrije Universiteit, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Somatostatin, Body Mass Index, Peptides, Cyclic. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Lanreotide is an effective and safe first-line therapy to treat patients with a gastroenteropancreatic (GEP) neuroendocrine tumor (NET). Precision oncology may be used to provide each patient with the right dosage. Pharmacokinetic data suggest lower exposure in higher weight patients. However, no recommendations for dose individualization in specific patient groups exist. Therefore, we aimed to investigate the association of body mass index (BMI), body surface area (BSA), and renal function on the efficacy and toxicity of lanreotide treatment for NETs.
Methods
GEP-NET patients on lanreotide treatment at Amsterdam UMC from 2016 to 2022 were included. Outcome measures were primarily PFS and secondarily OS and toxicity. Kaplan-Meier analyses and Cox’s proportional hazard models were used to calculate median PFS/OS and compare subgroups based on BMI, BSA, and renal function.
Results
A total of 122 patients with NETs of diverse origin, functionality, and grade were included with a median PFS of 28 months (95% CI, 19.3–36.7). The median OS was not reached. No statistically significant difference in PFS among BMI subgroups was observed, although obese patients had the longest PFS (52 months, 95% CI, 27.4–76.7) compared to other BMI categories. No relation between BSA/renal function and PFS or toxicity was found.
Conclusion
This large real-world data cohort of NET patients treated with lanreotide found no association of BMI, BSA, or renal function with PFS. Dose individualization of lanreotide treatment based on the patient characteristics BMI, BSA, or renal function does not seem rational based on these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Location Vrije Universiteit, Amsterdam, The Netherlands.
- Department of Medical Oncology, Amsterdam University Medical Center, Location Vrije Universiteit, Amsterdam, The Netherlands.
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Zitieren
APA
de Weert, I., Crul, M., Klümpen, H. J., & Schutte, T. (2025). Real-World Patient Outcomes on the Efficacy of Lanreotide Treatment for Neuroendocrine Tumors: The Influence of Body Mass Index, Body Surface Area, and Renal Function. Neuroendocrinology. https://doi.org/10.1159/000548257
Vancouver
de Weert I, Crul M, Klümpen HJ, Schutte T. Real-World Patient Outcomes on the Efficacy of Lanreotide Treatment for Neuroendocrine Tumors: The Influence of Body Mass Index, Body Surface Area, and Renal Function. Neuroendocrinology. 2025. doi:10.1159/000548257
BibTeX
@article{deWeert2025,
author = {de Weert, Ilse and Crul, Mirjam and Klümpen, Heinz-Josef and Schutte, Tim},
title = {Real-World Patient Outcomes on the Efficacy of Lanreotide Treatment for Neuroendocrine Tumors: The Influence of Body Mass Index, Body Surface Area, and Renal Function},
journal = {Neuroendocrinology},
year = {2025},
doi = {10.1159/000548257}
}
EUVIMED